Algorae Pharmaceuticals Limited (ASX: 1AI) has taken another step in building its commercial presence within the Australian pharmaceutical market. The Company has entered into a distribution agreement with Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY), marking a strategic shift from purely into tangible near-term revenue generation. The first shipment of Capecitabine 500mg tablets is scheduled to arrive in Australia in December 2025, positioning Algorae for an accelerated comme

Critical Resources Limited (ASX: CRR) continues to position its Mavis Lake Lithium Project in northwestern Ontario as one of the more advanced hard-rock lithium assets in the region (Figure 1). The Company has expanded its landholding by 25% to more than 400 km², strengthened its geological footprint, and advanced exploration to position the Project as a future supplier to the North American battery supply chain.

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.